ORIA · Orion Biotech Opportunities Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - |
| SG&A | - | $175.5K | $174.5K | $256.2K | - | $194.5K | $139.1K | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - | - |
| Operating Income | - | ($205.5K) | ($204.5K) | ($286.2K) | - | ($224.5K) | ($153.6K) | - |
| Interest Expense | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - |
| Net Income | - | $920.3K | $1.93M | $4.62M | - | $2.26M | ($2.05M) | - |
| EPS - Basic | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | $0.00 | - |
Balance Sheet
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $265.7K | $341.0K | $418.5K | $575.9K | $712.5K | $780.4K | $880.7K | - |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - |
| Accounts Payable | $7.7K | $13.0K | $5.3K | $23.4K | $11.6K | $6.6K | $14.5K | $22.0K |
| Current Assets | $439.3K | $633.2K | $821.0K | $1.10M | $1.35M | $1.56M | $1.80M | - |
| Total Assets | $203.33M | $201.83M | $201.12M | $201.12M | $201.36M | $201.56M | $201.80M | $376.3K |
| Current Liabilities | $67.6K | $58.0K | $40.3K | $110.0K | $81.6K | $82.9K | $97.8K | $396.3K |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $8.33M | $8.12M | $8.33M | $10.26M | $15.12M | $14.42M | $16.92M | - |
| Stockholders' Equity | ($7.79M) | ($7.39M) | ($7.41M) | ($9.14M) | ($13.76M) | ($12.86M) | $5.00M | ($20.1K) |
| Retained Earnings | ($7.79M) | ($7.39M) | ($7.41M) | ($9.14M) | ($13.76M) | ($12.86M) | ($2.09M) | ($45.1K) |
Cash Flow
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($136.6K) | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | - | 0.5% | 1.0% | 2.3% | - | 1.1% | -1.0% | - |
| Return on equity | - | -12.5% | -26.0% | -50.5% | - | -17.6% | -41.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 6.50 | 10.92 | 20.38 | 9.95 | 16.57 | 18.81 | 18.40 | - |
| Quick ratio | 6.50 | 10.92 | 20.38 | 9.95 | 16.57 | 18.81 | 18.40 | - |
| Cash ratio | 3.93 | 5.88 | 10.39 | 5.23 | 8.73 | 9.41 | 9.01 | - |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - |
| Equity multiplier | -26.09 | -27.32 | -27.15 | -22.01 | -14.64 | -15.67 | 40.36 | -18.73 |
| Liabilities / Assets | 0.04 | 0.04 | 0.04 | 0.05 | 0.08 | 0.07 | 0.08 | - |
| Efficiency | ||||||||
| Asset turnover | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 8.5% | -33.1% | - | - | - | - | - |
| Net income growth (YoY) | - | -59.4% | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 43.3% | 42.5% | - | -45391.5% | - | - | - | - |
Peer comparison
Same SIC group: Blank Checks
Comparing Orion Biotech Opportunities Corp. against the 5 most active filers in the same SIC group.